Sparrow Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel, targeted therapies to address unmet needs in both endocrinology and rheumatology.

We are developing novel therapies that address key limitations of current treatments for endocrine disorders such as endogenous Cushing’s syndrome (Cushing’s) and autonomous cortisol secretion (ACS), and autoimmune diseases such as polymyalgia rheumatica (PMR).

Backed by world-class investors, we are prepared to take our medical products through the entire development continuum – from clinical trials to regulatory approval, to commercialization.